CoChat
Sign Up
Cited by 61

miR‐144‐5p enhances the Radiosensitivity of non‐small‐cell lung Cancer cells via targeting ATF2

Song, Lei, Peng, Liping, Hua, Shucheng, Li, Xiaoping, Ma, Lianjun, Jie, Jing, Chen, Dong, Wang, Ying +1 more·2018·BioMed Research International
DOI 10.1155/2018/5109497PMC PMC5925000
Open this paper in CoChat — free account

Abstract

MicroRNAs (miRNAs or miRs) regulate gene expression at the posttranscriptional level and are involved in many biological processes such as cell proliferation and migration, stem cell differentiation, inflammation, and apoptosis. In particular, miR-144-3p is downregulated in various cancers, and its overexpression inhibits the proliferation and metastasis of cancer cells. However, the role of miR-144-5p in non-small-cell lung cancer (NSCLC), especially radiosensitivity, is unknown. In this study, we found that miR-144-5p was downregulated in NSCLC clinical specimens as well as NSCLC cell lines exposed to radiation. Enhanced expression of miR-144-5p promoted the radiosensitivity of NSCLC cells in vitro and A549 cell mouse xenografts in vivo. Furthermore, we identified activating transcription factor 2 (ATF2) as the direct and functional target of miR-144-5p using integrated bioinformatics analysis and a luciferase reporter assay. In addition, restoration of ATF2 expression inhibited miR-144-5p-induced NSCLC cell sensitivity to radiation in vitro and in vivo. Our findings suggest that deregulation of the miR-144-5p/ATF2 axis plays an important role in NSCLC cell radiosensitivity, thus representing a new potential therapeutic target for NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2018/5109497

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-144* (5p) directly targets ATF2.

    “miR‐144* (5p) directly targets ATF2, and it is possible that increased ATF2 levels upon reduced miR‐144* (5p) activity contributes to progression of NSCLC (Song et al., 2018).”

    From microRNA strand selection: Unwinding the rules (2021) · cites this paper as Song et al., 2018

  • miR-144* (5p) expression is down-regulated in nonsmall cell lung cancer (NSCLC).

    “miR‐144* (5p) expression is down‐regulated in nonsmall cell lung cancer (NSCLC) (Song et al., 2018), (Table 1).”

    From microRNA strand selection: Unwinding the rules (2021) · cites this paper as Song et al., 2018

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 37

  1. [1]Siegel R. Ma J. Zou Z. Jemal A. Cancer statistics, 2014 CA: A Cancer Journal for Clinicians 2014 64 1 9 29 10.3322/caac.21208 24399786 · DOI · Paper page
  2. [2]Benveniste M. F. K. Welsh J. Godoy M. C. B. Betancourt S. L. Mawlawi O. R. Munden R. F. New era of radiotherapy: An update in radiation-induced lung disease Clinical Radiology 2013 68 6 e275 e290 2-s2.0-84877070423 10.1016/j.crad.2013.01.013 23473474 PMC3941603 · DOI
  3. [3]Fox W. Scadding J. G. Medical research council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. ten-year follow-up The Lancet 1973 302 7820 63 65 10.1016/S0140-6736(73)93260-1 2-s2.0-0015802663 4123619 · DOI
  4. [4]Lee Y. S. Oh J.-H. Yoon S. Differential gene expression profiles of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation International Journal of Radiation Oncology • Biology • Physics 2010 77 3 858 866 10.1016/j.ijrobp.2009.12.076 2-s2.0-77952563228 20510196 · DOI
  5. [5]Kraus A. C. Ferber I. Bachmann S.-O. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways Oncogene 2002 21 57 8683 8695 2-s2.0-0037069932 10.1038/sj.onc.1205939 12483521 · DOI
  6. [6]MacFarlane L.-A. Murphy P. R. MicroRNA: biogenesis, function and role in cancer Current Genomics 2010 11 7 537 561 10.2174/138920210793175895 2-s2.0-78650004201 21532838 PMC3048316 · DOI
  7. [7]Sontheimer E. J. Carthew R. W. Silence from within: endogenous siRNAs and miRNAs Cell 2005 122 1 9 12 10.1016/j.cell.2005.06.030 2-s2.0-22144437679 16009127 · DOI
  8. [8]Croce C. M. Calin G. A. miRNAs, cancer, and stem cell division Cell 2005 122 1 6 7 10.1016/j.cell.2005.06.036 2-s2.0-22144461002 16009126 · DOI
  9. [9]Bartels C. L. Tsongalis G. J. Mini-reviews micrornas:novel biomarkers for human cancer Clinical Chemistry 2009 55 4 623 631 2-s2.0-64149132942 10.1373/clinchem.2008.112805 19246618 · DOI
  10. [10]Chen X. Xu Y. Liao X. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer Tumor Biology 2016 37 9 11927 11936 2-s2.0-84963699434 10.1007/s13277-016-5052-8 27075472 PMC5080326 · DOI
  11. [11]Ma Y. Xia H. Liu Y. Li M. Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt BioMed Research International 2014 2014 6 617868 10.1155/2014/617868 PMC3997135 24804226 · DOI
  12. [12]Jiang L.-P. He C.-Y. Zhu Z.-T. Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene Oncotarget 2017 8 14 23675 23689 10.18632/oncotarget.15644 2-s2.0-85016951092 28423589 PMC5410336 · DOI
  13. [13]Gao F. Liu P. Narayanan J. Changes in miRNA in the lung and whole blood after whole thorax irradiation in rats Scientific Reports 2017 7 2-s2.0-85015404996 10.1038/srep44132 44132 PMC5355888 28303893 · DOI
  14. [14]Bhoumik A. Takahashi S. Breitweiser W. Shiloh Y. Jones N. Ronai Z. ATM-dependent phosphorylation of ATF2 is required for the DNA damage response Molecular Cell 2005 18 5 577 587 2-s2.0-19444363740 10.1016/j.molcel.2005.04.015 15916964 PMC2954254 · DOI
  15. [15]Desai S. Kumar A. Laskar S. Pandey B. N. Differential roles of ATF-2 in survival and DNA repair contributing to radioresistance induced by autocrine soluble factors in A549 lung cancer cells Cellular Signalling 2014 26 11 2424 2435 2-s2.0-84906051973 10.1016/j.cellsig.2014.07.021 25041846 · DOI
  16. [16]Ronai Z. Yang Y.-M. Fuchs S. Y. Adler V. Sardana M. Herlyn M. ATF2 confers radiation resistance to human melanoma cells Oncogene 1998 16 4 523 531 2-s2.0-0032576820 10.1038/sj.onc.1201566 9484842 · DOI
  17. [17]Videtic G. M. M. The role of radiation therapy in small cell lung cancer Current Oncology Reports 2013 15 4 405 410 2-s2.0-84880788221 10.1007/s11912-013-0318-4 23625345 · DOI
  18. [18]Sirzén F. Kjellén E. Sörenson S. Cavallin-Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer Acta Oncologica 2003 42 5-6 493 515 10.1080/02841860310014453 2-s2.0-0141636528 14596509 · DOI
  19. [19]Carmichael J. Degraff W. G. Gamson J. Radiation sensitivity of human lung cancer cell lines European Journal of Cancer and Clinical Oncology 1989 25 3 527 534 2-s2.0-0024515281 10.1016/0277-5379(89)90266-6 2539297 · DOI
  20. [20]Gandellini P. Rancati T. Valdagni R. Zaffaroni N. miRNAs in tumor radiation response: bystanders or participants? Trends in Molecular Medicine 2014 20 9 529 539 2-s2.0-85027939436 10.1016/j.molmed.2014.07.004 25153824 · DOI
  21. [21]Mueller A.-K. Lindner K. Hummel R. Haier J. Watson D. I. Hussey D. J. MicroRNAs and Their Impact on Radiotherapy for Cancer Journal of Radiation Research 2016 185 6 668 677 2-s2.0-84976499396 10.1667/RR14370.1 27223830 · DOI
  22. [22]Meijer H. A. Smith E. M. Bushell M. Regulation of miRNA strand selection: follow the leader? Biochemical Society Transactions 2014 42 4 1135 1140 10.1042/bst20140142 2-s2.0-84905854260 25110015 · DOI · Paper page
  23. [23]Gao F. Wang T. Zhang Z. Wang R. Guo Y. Liu J. Retracted Article:Regulation of activating protein-4-associated metastases of non-small cell lung cancer cells by miR-144 Tumor Biology 2016 37 12 15535 15541 10.1007/s13277-015-3866-4 2-s2.0-84938787036 26254097 · DOI
  24. [24]Li B. Zhang S. Shen H. Li C. MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3 Biochemical and Biophysical Research Communications 2017 484 2 241 247 2-s2.0-85010843453 10.1016/j.bbrc.2017.01.084 28111340 · DOI
  25. [25]Pan Y. Zhang J. Fu H. Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process OncoTargets and Therapy 2016 9 6247 6255 2-s2.0-84991716183 10.2147/OTT.S103650 27785072 PMC5067005 · DOI
  26. [26]Liu S. Luan J. Ding Y. MiR-144-3p Targets FosB Protooncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells Oncology Research: Featuring Preclinical and Clinical Cancer Therapeutics 2017 10.3727/096504017X14982585511252 PMC7844736 28653602 · DOI
  27. [27]Liang H.-W. Ye Z.-H. Yin S.-Y. A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma OncoTargets and Therapy 2017 10 3405 3419 2-s2.0-85024125293 10.2147/OTT.S138143 28744145 PMC5513884 · DOI
  28. [28]Gao Z. Liu R. Liao J. Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis Molecular Medicine Reports 2016 14 4 3805 3813 2-s2.0-84988535748 10.3892/mmr.2016.5691 27572636 · DOI
  29. [29]Li C. Y. Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression Clinical Translational Oncology 2017 19 2 162 172 27173517
  30. [30]Chang C.-W. Wu H.-C. Terry M. B. Santella R. M. MicroRNA expression in prospectively collected blood as a potential biomarker of breast cancer risk in the BCFR Anticancer Reseach 2015 35 7 3969 3978 2-s2.0-84937121763 PMC4776637 26124344
  31. [31]Matsushita R. Seki N. Chiyomaru T. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer British Journal of Cancer 2015 113 2 282 289 2-s2.0-84937073589 10.1038/bjc.2015.195 26057453 PMC4506384 · DOI
  32. [32]Lopez-Bergami P. Lau E. Ronai Z. Emerging roles of ATF2 and the dynamic AP1 network in cancer Nature Reviews Cancer 2010 10 1 65 76 2-s2.0-72949113230 10.1038/nrc2681 20029425 PMC2874064 · DOI
  33. [33]Watson G. Ronai Z. Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease Pharmacological Research 2017 119 347 357 2-s2.0-85014452409 10.1016/j.phrs.2017.02.004 28212892 PMC5457671 · DOI
  34. [34]Reimold A. M. Grusby M. J. Kosaras B. Chondrodysplasia and neurological abnormalities in ATF-2-deficient mice Nature 1996 379 6562 262 265 2-s2.0-13344278032 10.1038/379262a0 8538792 · DOI
  35. [35]Maekawa T. Bernier F. Sato M. Mouse ATF-2 null mutants display features of a severe type of meconium aspiration syndrome The Journal of Biological Chemistry 1999 274 25 17813 17819 2-s2.0-0033580843 10.1074/jbc.274.25.17813 10364225 · DOI
  36. [36]You Z. Zhou Y. Guo Y. Chen W. Chen S. Wang X. Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma Oncology Letters 2016 11 1 760 766 2-s2.0-84948807729 10.3892/ol.2015.3922 26870280 PMC4727085 · DOI
  37. [37]Lo Iacono M. Monica V. Vavalà T. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway International Journal of Cancer 2015 136 11 2598 2609 2-s2.0-84924860249 10.1002/ijc.29302 25359574 · DOI

Cited by

Sorted by citations

Authors
Song, L., Peng, L., Hua, S., Li, X., Ma, L., Jie, J., Chen, D., Wang, Y., & Li, D.
Affiliations
  • Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, China
  • Department of Pediatrics, The First Hospital of Jilin University, Changchun, Jilin 130021, China
  • Endoscopy Center, The China-Japan Union Hospital of Jilin University, 146 Xiantai Street, Changchun, Jilin 130021, China
ORCID
Venue
BioMed Research International
Publisher
Wiley
Published
2018
Volume
2018
Pages
1-10
ISSN
  • 2314-6133
  • 2314-6141
DOI
10.1155/2018/5109497
PMC
PMC5925000
Cited by
61
References
0
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)
Funders
Project of Science and Technology Agency of Jilin Province (20180520130JH, 2017062209JC)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review